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A peptide containing residues 1–50 of the Aα-chain of fibrinogen,
expressed as a fusion peptide with β-galactosidase, is rapidly
cleaved by thrombin at Arg-16, similarly to whole fibrinogen.
When Phe-8, which is highly conserved, is replaced with tyrosine
(F8Y), the cleavage is slowed drastically [Lord, Byrd, Hede, Wei
and Colby (1990) J. Biol. Chem. 265, 838–843]. To examine the
structural basis for this result, we have determined the crystal
structure of bovine thrombin complexed with a synthetic peptide
containing residues 1–23 of fibrinogen Aα and the F8Y mutation.




2, with unit-cell dimensions
of a¯ 88.3 AI (1 AI ¯ 0.1 nm), c¯ 195.5 AI and two complexes in
the asymmetric unit. The final R factor is 0.183 for 2σ data from
INTRODUCTION
Thrombin (EC 3.4.21.5), a serine endoprotease that preferentially
cuts after arginine and sometimes lysine residues, is both a major
product and a major regulator of the clotting cascade in
thrombosis and haemostasis [1,2]. Bovine α-thrombin has an A-
chain of 49 residues that is linked, via a single disulphide bond,
to a B-chain of 259 residues that contains the catalytic residues,
His-57, Asp-102 and Ser-195. ²The residue numbers for thrombin
in this paper are assigned by analogy with chymotrypsin [3].
Sequential capital letters are used for thrombin residues inserted
into the sequence of chymotrypsin, e.g. the five residues of the
autolysis loop inserted at position 149 (Thr-149A to Glu-149E).
Sequence numbers for fibrinogen are identified by the suffix f.´
Structures of bovine thrombin (TBN) complexed with residues
7–16 of fibrinopeptide A (FpA7) [4] and G17ψ [5] (defined in
Table 1), with hirudin [6], and with small-molecule inhibitors [7],
are known. Structures have also been determined for similar
complexes involving human thrombin [3,8–10].
Thrombin is more specific than other serine proteases such as
trypsin because of several striking insertions in the primary
structure. Thrombin binds the peptide substrate in a groove that
is deeper, longer and less accessible than that of similar proteases
[3]. The specificity is provided by (1) an extended, apolar binding
site for hydrophobic residues on the N-terminal side of the
scissile bond, (2) a specificity pocket with a strong preference for
arginine, (3) subsites for small, non-polar residues immediately
after the scissile bond, and (4) a strongly basic groove that binds
Abbreviations used: Fp, fibrinopeptide ; RMS, root mean square ; TBN; bovine thrombin.
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7.0 to 2.5 AI resolution. There is continuous density for the five
residues in the P3, P2, P1, P1« and P2« positions of the peptide
(Gly-14f to Pro-18f) at the active site of thrombin, and isolated
but well-defined density for Tyr-8f at position P9 in the hydro-
phobic pocket of thrombin. The tyrosine residue is shifted
relative to phenylalanine in the native peptide because the phenol
side chain is larger and makes a novel, intrapeptide hydrogen
bond with Gly-14f. Adjacent peptide residues cannot form the
hydrogen bonds that stabilize the secondary structure of
the native peptide. Consequently, the ‘reaction’ geometry
at the scissile bond, eight residues from the mutation, is perturbed
and the peptide is mostly uncleaved in the crystal structure.
macromolecule ligands such as fibrinogen, the thrombin receptor
and hirudin at acidic residues C-terminal to the scissile bond [11].
During clotting, thrombin cleaves the two Aα-chains of
fibrinogen rapidly at Arg-16f and the two Bβ-chains more slowly
at Arg-14f to release FpA and FpB respectively. Active site





fusion proteins has shown that the first six
residues of FpA do not affect the activity, whereas Asp-7f, Phe-
8f, Gly-12f, Gly-13f, Val-15f and Arg-16f are required for
maximal activity [12–15]. These residues occupy respectively the
P10, P9, P5, P4, P2 and P1 positions of the substrate (Table 1).




when added to a synthetic peptide,
is unusually important given its distance from the scissile bond
[16]. An explanation for this anomaly is apparent in the three-
dimensional structure of the complex of FpA7 with thrombin, in
which the first five residues, Asp-7f to Glu-11f, form a turn of α-
helix that brings Phe-8f back into the active site, where it lies in
a hydrophobic cage next to Val-15f [4,5,10,17]. This inter-
action is critical. When Phe-8f is replaced with tyrosine in a
fusion protein containing residues 1–50 of the Aα-chain,
the fusion protein changes from being an excellent substrate to
being an excellent inhibitor [12]. This surprising transformation
cannot be due to a simple disruption of the α-helical turn. With
a disordered N-terminus, the peptide should still bind using
merely the immediate residues around the scissile bond, in the
same fashion as short fibrinopeptides which are cleaved [18].
To understand these observations, we have synthesized the
first 23 residues of the Aα-chain – with a tyrosine residue
816 M. G. Malkowski and others
Table 1 Sequences (one-letter amino acid codes) and nomenclature for fibrinogen Aα peptides
The ‘P ’ nomenclature is from [37]. Sn and Sn« are used for the subsites on thrombin that bind the Pn and Pn« substrate residues. A blank in the table indicates the residue is not part of the
peptide. A bullet point indicates that the residue is the same as in F8Y. FpA7, G17ψ and G12V have an acetylated N-terminus. ψ denotes psuedoglycine with -CH2- replacing the -NH- group.
Residue 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
‘P ’ no. 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 1« 2« 3« 4« 5« 6« 7«
F8Y A D S G E G D Y L A E G G G V R G P R V V E R
FpA7 E F E E E E E E E E
7ψ E F E E E E E E E E ψ E E
G12V E F E E E V E E E E
replacing Phe-8f (peptide F8Y; Table 1) – and co-crystallized the
peptide with TBN. We find that this variant peptide is not
cleaved by human α-thrombin in solution or by bovine α-
thrombin in the crystal.
MATERIALS AND METHODS
Preparation of proteins
TBN was prepared as described previously [19] and had between
1500 and 2000 NIH units per mg of protein. The protein was
stored at ®80 ° C in ammonium phosphate buffer, pH 6.5. The
F8Y peptide, corresponding to N-terminal residues 1–23 of the
fibrinogen Aα-chain (Table 1), with Phe-8 mutated to tyrosine,
was synthesized by the protein chemistry facility of UNCCH}
NIEHS, and was more than 90% pure as assessed by HPLC.
HPLC and mass spectrometric analysis
To determine whether this peptide is a substrate for thrombin,
the peptide in 50 mM Tris}HCl (pH 7.4)}150 mM NaCl at
1.8 µM final concentration was incubated with or without
9 units}ml human α-thrombin at 37 °C for 120 min. The samples
were then heated at 100 °C for 2 min to stop the reaction, and
centrifuged. Aliquots of each supernatant were loaded on a
reverse-phase HPLC C
")
column with buffer A (25 mM sodium
phosphate, pH 6.0) and eluted with a linear gradient of buffer B
[50 mM sodium phosphate (pH 6.0)}50% (v}v) acetonitrile] as
previously described [20]. HPLC tracings after 120 min at 37 °C
with or without thrombin showed no cleavage of the peptide
(Figure 1). Matrix-assisted laser desorption ionization MS
(MALDI-MS) was performed by the Protein and Carbohydrate
Structure Facility (University of Michigan, Ann Arbor, MI,
U.S.A.) on protein crystals that had been isolated, collected and
dissolved in 50% (v}v) acetonitrile in distilled water.
Crystallization
The TBN–F8Y complex was prepared by mixing the peptide at
a final concentration of 5 mM with a 0.4 mM solution (15 mg}ml)
of TBN in 0.25 M ammonium phosphate, pH 6.0. The crystals
used for data collection appeared in hanging drops equilibrated







(pH 7.5)}2% PEG400 for 7 days and were harvested after 12
days.
Data collection
Diffraction data were collected at room temperature on two
crystals of the F8Y complex (1.1 mm¬0.3 mm¬0.3 mm and
Figure 1 HPLC elution profiles
The F8Y peptide at 1.8 µM was incubated (a) alone and (b) with 9 units of human thrombin
for 120 min and then analysed by HPLC on a C18 column as described in the text. Thrombin
was eluted at approx. 8% buffer B whereas F8Y was eluted at approx. 32% buffer B.
0.6 mm¬0.2 mm¬0.2 mm; 5 days old) mounted in quartz
capillaries by using a Siemens area detector with a Rigaku
RU200H rotating-anode X-ray source (40 kV, 70 mA) and a
Supper graphite monochromator (CuKα radiation). The data
collection, which was organized with the program ASTRO [21],
was done at four different fixed φ values ; a total of 880 frames,
each 0.25 ° in ω, were collected. The data from the two crystals,
which were scaled and merged separately with the program
XENGEN [22], had R
sym
values of 0.052 and 0.081 respectively,
and an overall R
merge
of 0.109 for 18614 unique reflections when
the two separate data sets were combined by using the DIFCOR
program in the ROCKS suite of programs [23]. The combined
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Figure 2 The electron density for Tyr-8f
Tyr-8f (thick lines), and its 2Fo–Fc ‘ omit ’ electron density contoured at 0.8σ are shown in stereo for (a) complex I and (b) complex II. Thrombin residues Tyr-60A, Trp-96, Leu-99, Ile-145 and
Trp-215, which form a hydrophobic pocket, are shown in thin lines.
data set had an overall completeness of 63% for data from 7.0
to 2.5 AI (1 AI ¯ 0.1 nm) resolution (25% complete at 2.6–2.5 AI
resolution) in the last shell.
Structure solution





¯ b¯ 88.3 AI , c¯ 195.5 AI ) and are isomorphous with those of
TBN complexed with the G12V fibrinopeptide (Table 1), which
were solved before this project by molecular replacement (P. D.
Martin, M. Malkowski and B. Edwards, unpublished work) by
using XPLOR [24] and TBN [4] as the model. Those calculations




2 with two crystallo-
graphically independent TBN–G12V complexes in the asym-





¯ 77.5 °, θ
$
¯ 83.3 ° ; thrombin II at θ
"
¯ 163.4 °, θ
#
¯ 78.5 °, θ
$
¯ 75.2 °) and separated by approx. 0.5 of the c-axis.
This rather unusual arrangement was verified by an ‘omit ’




electron density map calculated with phases from thrombin in
complex I alone and improved with SQUASH [25] showed long
stretches of main-chain density that fitted the β-sheet and α-
helical sections of thrombin in complex II. When the electron
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Figure 3 F8Y residues at the active site
Residues Gly-14f to Pro-18f (thick lines) are shown in stereo with the 2Fo–Fc ‘ omit ’ electron density calculated in XPLOR. The electron density is contoured at 0.8σ for (a) complex I and (b)
complex II. The scissile bond, between Arg-16f and Gly-17f, is mostly intact as shown by the continuous electron density throughout the peptide. Thrombin residues have been left out for clarity.
zeroed and the modified map back-transformed to produce a
new set of structure factors, molecular replacement calculations
gave a strong solution for thrombin II. This method of subtractive
molecular replacement and modifications to it have proved
useful in solving other thrombin crystals with multiple complexes
in the asymmetric unit [26].
Structural analysis
The coordinates for the crystal structures of human PPACK-
thrombin (entry 1PPB), TBN complexed with FpA residues 7–16
(TBN–FpA7; entry 1BBR) TBN complexed with FpA residues
7–19, with a non-cleavable scissile bond (TBN–G17y; entry
1UCY), and Streptomyces griseus protease B complexed with
turkey ovomucoid inhibitor (entry 3SGB) were obtained from
the Protein Data Bank [27]. Hydrogen bonds were calculated
with the program QUANTA (Molecular Simulations, San Diego,
CA, U.S.A.). The criteria for a hydrogen bond are that the three
angles C?OIH, OIH–N, and H–N–C be greater than 90 °
and the distance NIO not exceed 3.3 AI for a ‘short ’ hydrogen
bond and 4.0 AI for a ‘ long’ one [28]. Superposition of coordinates
between structures was done with the program ALIGN [29] and
the Cα coordinates of the thrombin residues unless stated
otherwise. ‘Omit ’ maps were calculated in XPLOR.
RESULTS
Refinement
The refinement began with two thrombin molecules in the
asymmetric unit, each with 36 A-chain residues (1H–15) and 259
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Figure 4 Fibrinopeptide F8Y in complex I and complex II
The F8Y peptide in complex I (thick lines) is compared with F8Y in complex II (thin lines) after the two complexes were overlapped by using only thrombin Cα coordinates.
Table 2 Thrombin interactions with F8Y fibrinopeptides I and II compared
with those with the G17ψ substrate analogue
G17ψ-III is complex III in the TBN–G17ψ crystal structure [5]. Note : 1 AI 3 0.1 nm.
Distance (AI )
Fibrinopeptide atom Thrombin atom F8Y-I F8Y-II G17ψ-III
Tyr/Phe-8f N Lys-97 O 2.5 2.7 2.8
Glu-97A O 3.1
Tyr-8f OH Gly-14f N 2.2 2.7*
Gly-14f N Gly-216 O 2.2 3.0
Tyr-8f OH 2.2 2.7*
Gly-14f O Gly-216 N 2.8 3.1
Arg-16f N Ser-195 OG 3.1 3.1
Ser-214 O 3.1
Gly-14f O 2.9
Arg-16f O Gly-193 N 2.9 3.0 2.8
Ser-195 N 3.0
Arg-16f NE Ala-190 O 3.3
Gly-219 O 3.2
Arg-16f NH1 Asp-189 OD2 3.1 2.9
Trp-215 O 3.2
Arg-16f NH2 Asp-189 OD1 3.2 2.5 2.9
Asp-189 OD2 3.1
Gly-219 O 2.7 3.0 2.8
* Angle of 83 ° is slightly less than 90 ° limit.
B-chain residues (16–247), and data from the first crystal only.
By using XPLOR, the R factor was reduced from 0.406 to 0.362
with 50 cycles of rigid-body refinement and further reduced to
0.236 for data from 7–3.2 AI resolution with 120 cycles of





map allowed us to fit residues Tyr-8f and Gly-14f to Pro-18f of
the F8Y fibrinopeptide in both complexes. After 120 additional
cycles of positional refinement, the R factor was 0.195 for data
from 7–3.2 AI resolution.
Subsequent refinement was done with the merged data from
both crystals (7–2.5 AI resolution; rF
hkl
r" 2σ). Residues with




electron density map, namely
the six N-terminal residues and the C-terminal residue of the A-
chain (1H–1C; Arg-15), the autolysis loop (147–149E), and the
C-terminus of the B-chain (244–247) were removed before
proceeding with further refinement. A total of 276 water
molecules were then added at positions that were within 2.5–3.5 AI









maps. Final cycles of positional refinement in
GPRLSA [30] and temperature factor refinement in XPLOR
decreased the R factor to 0.183 for 2σ data from 7–2.5 AI
resolution.
The final refined model of TBN–F8Y had root mean square
(RMS) deviations from reference values of 0.015 AI on bonds,
2.48 ° on angles, 1.34 ° on impropers and 24.58 ° on dihedrals.
On the Ramachandran plot calculated with PROCHECK [31],
78% of the residues lay in the most favoured regions (compared
with a typical value of 77% for other structures at 2.5 AI
resolution), 21% in additionally allowed regions and 1% (five
residues) in disallowed regions. The nine other parameters
evaluated by PROCHECK were within the bounds established
from well-refined structures at equivalent resolution or on the
better side of these regions. The average coordinate error [32] of
the structure was 0.25–0.30 AI as determined in XPLOR. When
the final model was subjected to simulated annealing at 4000 K
by using 95% of the data, R
free
started at 0.303 and decreased to
0.245 after positional refinement.
Thrombin
The two independent thrombin molecules in complexes I and II
include residues 1B–14M of the A-chain, and residues 16–146
and 150–243 of the B-chain. There is no density for the first 13
residues of the A-chain or for the single carbohydrate chain
attached to Asn-60G. Residues 1H–1C at the A-chain N-
terminus, residue 15 at the A-chain C-terminus, and residues
244–247 at the B-chain C-terminus, have poor density and are
not in the model. The autolysis loop, corresponding to residues
145–150 of the thrombin B-chain, has fragmented density and
has also been removed.However, the electron density is consistent
with complex I’s being bovine α-thrombin cut between residues
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Figure 5 Comparison of F8Y with the non-cleavable substrate analogue G17ψ
Residues 8f and 14f–18f of F8Y (thick lines) are shown in stereo for (a) complex I and (b) complex II overlapped with the corresponding residues of TBN–G17ψ (thin lines).
Ala-149A and Asn-149B (ε-thrombin) and complex II’s being α-
thrombin in a manner similar to that seen in crystals of
TBN–FpA7 and TBN–G17ψ [4,5].
The RMS deviation in Cα coordinates is 0.46 AI when the
two complexes are compared together ; 0.51 and 0.52 AI re-
spectively when the two complexes are compared against
PPACK-thrombin [3] ; and 0.46 and 0.46 AI respectively when
compared with TBN–FpA7 (complex III in [4]). These deviations
indicate that the structures of the two complexes are very close
to one another and to other well-refined thrombin structures. A
total of 37 residues, in either one or both thrombin molecules,
have RMS deviations greater than 1.0 AI at their Cα positions.
These deviations are reasonable given that the residues lie at the
termini of the A-chain or B-chain, or contact symmetry-related
molecules or reside in mobile surface loops as evidenced by
temperature factors well above the average values of 15.5 and
22.6 AI # for thrombin in complexes I and II respectively.
Fibrinopeptide
There was no electron density for residues 1–7 of the fibrino-
peptide, confirming previous published reports that the first six
residues of the fibrinopeptide do not interact with thrombin
[13,14,33,34]. Well-defined electron density was seen for residue
Tyr-8f and for residues Gly-14f to Pro-18f but there was no
interpretable density for Leu-9f to Gly-13f (Figures 2 and 3).
Instead of following the same path as that seen in TBN–FpA7
andTBN–G17ψ, these five intervening residues forma disordered
linker chain through open solvent regions. As a consequence,
part of the original path is now occupied by crystal contacts.
There was also no electron density for the last five residues of the
F8Y peptides, Arg-19f to Arg-23f.
The two F8Y peptides, which had an RMS deviation of 1.1 AI
in Cα positions relative to one another (Figure 4), bound in
similar but not identical orientations (Table 2). Although Tyr-8f
in both F8Y complexes has moved relative to the position of
Phe-8f in FpA7 or G17ψ (Figure 5), it still makes the strong
hydrogen bond between the backbone NH at position 8f and the
carbonyl oxygen of Lys-97 that is present in the TBN–G17ψ and
TBN–FpA7 complexes [4,5]. The side chain of Tyr-8f, like that
of Phe-8f, lies within the hydrophobic pocket formed by thrombin
residues Tyr-60A, Leu-99, Ile-174 and Trp-215 and the side chain
ofVal-15f. In complex II, Tyr-8f contacts Trp-60D in a symmetry-
related molecule as well. This contact is the only packing
interaction involving either F8Y peptide. Uniquely to F8Y, the
phenol side chain of Tyr-8f forms an intrapeptide hydrogen bond
with Gly-14f NH (Table 2).
Perhaps owing to the interaction with Tyr-8f, Gly-14f makes
a single hydrogen bond with Gly-216 (Table 2), in contrast with
the G17ψ peptide and most other serine protease inhibitors,
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which make both possible hydrogen bonds. Val-15f lies between
thrombin residues Trp-60D and Leu-99, where its side chain
forms part of the hydrophobic cage surrounding Tyr-8f. It has
no hydrogen bonds with thrombin (Table 2) but does form an
intrapeptide hydrogen bond in complex I with Gly-17f.
In both TBN–F8Y complexes, the side chain of Arg-16f is
hydrogen-bonded to Asp-189 and Gly-219 in the specificity
pocket. However, in complex I there is also a hydrogen bond
with Ala-190 and in complex II a hydrogen bond with Trp-215
(Table 2). Likewise, the main chain of Arg-16f is hydrogen-
bonded to Gly-193 in all three complexes, but hydrogen bonds
with Ser-214, Ser-195 and Gly-14f are also seen in at least one of
the complexes. Gly-17f has no polar interactions with thrombin
in the F8Y complexes. Although Pro-18f is in approximately the
same S2« site as in the G17ψ complexes, it is shifted more
towards the solvent and is not packed as tightly against the
carbonyl oxygens of Leu-40 and Leu-41 (Figure 5).
DISCUSSION
Structure of the thrombin molecules
The two thrombin molecules in the asymmetric unit are crystallo-
graphically independent but have almost identical tertiary
structures. Residues exhibiting differences larger than 1.0 AI , i.e.
more than twice the RMS deviation, are generally located at
mobile termini or loops or crystal packing contacts. An exception
occurs at the ‘YPPW loop’, Tyr-60A to Trp-60D, which usually
shows little variation between thrombin structures [35]. The loop
is well defined in both F8Y complexes, as indicated by the low
average B values of 13 and 16 AI # respectively, but the two loops
have RMS deviations of 0.9 and 1.4 AI respectively relative to
TBN–G17ψ, and 1.2 AI relative to each other. The movement
maintains the hydrophobic contact seen in previous studies with
the side chain of Val-15f [4,5,10], which has a different position
in each F8Y complex (Figure 4).
Fibrinopeptide structure and interactions with thrombin
The canonical structure of FpA bound to thrombin consists of a
single turn of helix, formed by Asp-7f to Glu-11f, which is linked
via Gly-12f and a type I β-bend, involving residues Leu-9f to
Gly-12f, to an extended chain of residues Gly-13f to Arg-16f
[4,5,10]. Positions for residues Gly-17f to Arg-19f (P1«–P3«) are
known from the structure of thrombin complexed with G17ψ, an
uncleavable substrate analogue, in which the scissile peptide
bond is replaced by a ketone–methylene carbon bond [5]. In
TBN–F8Y, Arg-19f to Arg-23f do not have corresponding
electron density and are disordered.
In TBN–FpA7 and TBN–G17ψ the turn of helix and the β-
bend are stabilized almost exclusively by intrapeptide hydrogen
bonds. The only interactions with thrombin, besides the hydro-
phobic cage around Phe-8f, are a hydrogen bond between the
amide nitrogen of Phe-8f and the carbonyl oxygen of Lys-97 and
a salt bridge between the side chains of Glu-11f and Arg-173. The
next significant interaction with thrombin does not occur until
Gly-14f, which makes the antiparallel β-strand hydrogen bonds
with Gly-216.
Although the salt bridge does not exist in TBN–F8Y, Glu-11f
has no density and the side chain of Arg-173 is rotated away to
hydrogen bond with water molecules, Tyr-8f retains most of the
hydrophobic interactions and also the main-chain hydrogen
bond with Lys-97. However, in both TBN–F8Y complexes the
carbonyl oxygen of Tyr-8f, which participates in multiple intra-
peptide hydrogen bonds that stablilize the secondary structure in
TBN–FpA7 and TBN–G17ψ, has moved by 1.8 AI in both F8Y
complexes. Apparently, this large shift weakens the intrapeptide
interactions to the point that the helix becomes unstable. Tyr-8f
is shifted from the position of Phe-8f because the phenol group
is larger and makes a new hydrogen bond with the amide
nitrogen of Gly-14f (Table 2). The phenol ring does not retain the
edge-to-face stacking with Trp-215 seen for Phe-8f in TBN–FpA7
and TBN–G17ψ.
The peptide secondary structure is also probably disordered or
only weakly present in solution. The TBN–F8Y complex, which
is crystallized under essentially the same conditions as the
TBN–FpA7 and TBN–G17ψ, forms a quite different unit cell in
which residues from symmetry-related complexes actually over-
lap the path that the peptide would follow if it retained the
canonical turns. If the peptide turns were as stable in TBN–F8Y
as in the other fibrinopeptide complexes, this crystal packing
would not be possible.
In the TBN–G17ψ complexes, Gly-17f has only van der Waals
contacts, Pro-18f contacts the carbonyl oxygens of Leu-40 and
Leu-41, and Arg-19f interacts with Glu-192 in one orientation
and Glu-39 in an alternative orientation [5]. However, in TBN–
F8Y the carbonyl carbon of Pro-18f is displaced by 1.5 and 2.1 AI
respectively towards the solvent in complexes I and II relative to
Pro-18f in the G17ψ complex (Figure 5). Consequently, Arg-19f
cannot make the same interactions as in the substrate analogue
complex and is shifted out into the solvent instead. In agreement
with this analysis, the side chains of Glu-39 and Glu-192 have
moved away from their positions in the TBN–G17ψ complex.
Val-20f has been postulated to interact with Phe-60H [35]. In
the F8Y complexes, Val-20f has no electron density and therefore
the proposed interaction with Phe-60H cannot be evaluated.
However, the Cα atom of Pro-18f, the last F8Y peptide residue
seen in our structure, is 14.7 AI from the Cα atom of Phe-60H.
Residues Val-21f to Arg-23f do not increase the specificity
constant [18] and therefore are not expected to interact signifi-
cantly with thrombin; they are probably part of an external loop
that links the cleavage site with the sequence that binds at the
fibrinogen recognition exosite [35].
Catalytic site
In both complexes the electron density for the scissile bond and





‘omit ’ electron density maps calculated in XPLOR
(Figure 3). However, the overall temperature factors for F8Y in
complexes I and II are 53.1 and 59.9 AI # respectively, almost three
times the average overall temperature factor for the entire
structure (22.3 AI #). These elevated B values for F8Y are probably
due to some combination of higher mobility, partial occupancy
or partial cleavage of F8Y. The electron density in the unbiased
‘omit ’ map (Figure 3) shows that a significant portion of the
F8Y peptide in both crystallographically independent complexes
is uncleaved. However, hydrolysis does continue slowly. Mass
spectrometric analysis on 14 dissolved TBN–F8Y crystals that
were harvested from drops equilibrated for 21 days showed a
peak for FpA at 1554 Da but no peaks at higher molecular
masses. When the crystal structure was refined as a cleaved,
product complex, Gly-17 and Pro-18 did not fit the electron
density (results not shown). Moreover, if F8Y were fully cleaved,
the P«1 and P«2 residues, which have limited interactions with
thrombin, would not be present, as shown by the structure of
TBN–FpA7 [9]. In these crystals, which are grown under
conditions similar to those used for F8Y, there is no electron
density for residues beyond Arg-16f, although the FpA7 peptide
was synthesized as Asp-7f to Asp-20f. The FpA7 peptide is
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Table 3 Ramachandran angles for P3 to P«3
Canonical angles are from [38]. Angles in parentheses are outside the canonical range.
Angle (degrees)
Canonical limits G17ψ-III F8Y-I F8Y-II
Position φ ψ φ ψ φ ψ φ ψ
P3 G14f ®120/®140 140–170 ®136 (122) – (113) – (®159)
P2 V15f ®60/®100 139–180 ®68 157 (®59) (105) ®75 (92)
P1 R16f ®95/®120 9–50 ®101 29 (®59) 19 (®78) (66)
P«1 G17f ®60/®100 139–180 ®74 166 ®68 151 (®145) 173
P«2 P18f ®99/®140 70–120 ®70 132 (®41) (176) (®39) 119
P«3 R19f ®99/®140 70–120 ®102 (3) – – – –
Table 4 Active site geometry
Angle (degrees)
Distance (AI )
Complex OγI C–O* OγI C–Ca OγI C–N OγI C
Optimum* 90 90 90
G17ψ-III† 90 92 85 2.6
F8Y-I 88 84 99 2.4
F8Y-II 64 82 134 3.8‡
Ovomucoid 95 84 97 2.7
* From [36].
† The angles and distances are measured from the Oγ of Ser-195 to the substrate atoms.
‡ Ser-195 Oγ and carbonyl carbon atom of F8Y-II are both displaced by 0.7 AI from the
positions in the G17ψ substrate analogue. The distance from Ser-195 Oγ in F8Y-II to the
carbonyl carbon in the overlapped substrate analogue (i.e. the ideal position) is 3.1 AI .
rapidly cleaved at Arg-16f during crystallization and the last four
residues do not bind to thrombin [4].
Because the peptide secondary structure is disordered, F8Y
binds at the catalytic site with torsion angles that differ signifi-
cantly from the canonical values and from the values of the
G17ψ substrate analogue (Table 3). As a consequence, the F8Y
peptides in complexes I and II have RMS deviations of 1.1 and
0.9 AI respectively when compared with the substrate analogue
(Figure 5) and have distorted catalytic geometry (Table 4).
Although the F8Y peptide has a susceptible Arg-16f–Gly-17f
bond and is bound to active thrombin, as evidenced by cata-
lytically appropriate hydrogen bonds between Ser-195, His-57
and Asp-102 (2.5–2.8 AI ), the peptide is cleaved at a much lower
rate because F8Y binds with geometry that is incompatible with
nucleophilic attack by Ser-195 on the carbonyl carbon. Theor-
etical calculations show that the reaction proceeds optimally
when the serine hydroxy oxygen, carbonyl carbon and carbonyl
oxygen make a right-angled triangle (angle OGIC?O of 90 °)
that is perpendicular to the plane of the scissile peptide bond [36].
The substrate analogue, G17ψ, binds almost exactly in this
fashion (Table 4). In contrast, F8Y is a very poor substrate
because it binds with a reaction geometry that is non-ideal, like
a natural peptide inhibitor such as turkey ovomucoid bound to
trypsin (Table 4). Thus the interaction of Phe-8f with the apolar
site in thrombin is critical for the proper orientation of the
scissile bond and efficient nucleophilic attack by Ser-195.
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